Every Form 4 that Spyre Therapeutics, Inc. (SYRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SYRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRE filings page.
Spyre Therapeutics, Inc. Chief Legal Officer and Corporate Secretary Heidy King-Jones exercised options for 28,933 common shares at $14.50 per share on October 1, 2026, then sold 28,933 shares in five transactions under a Rule 10b5-1 trading plan adopted April 16, 2026. The sales had weighted-average prices of $89.24 (400 shares), $90.35 (16,605), $91.35 (7,228), $92.70 (2,100), and $93.46 (2,600) per share. The reported post-exercise stock-option position was 482,478 underlying shares.
Spyre Therapeutics, Inc. (SYRE) Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock on October 1, 2026, in six transactions under a Rule 10b5-1 trading plan adopted June 20, 2025. Reported per-share prices were $89.1400, $90.1000, $91.4900, $92.3100, $93.3700 and $93.9100; the first five were weighted averages.
Spyre Therapeutics, Inc. (SYRE) Chief Financial Officer Scott L. Burrows exercised options for 17,500 shares on September 30, 2026, at a $14.50 exercise price, then sold 17,500 common shares at a weighted-average $89.89 per share; prices ranged from $89.00 to $90.62. On October 1, he exercised options for 7,500 shares at $14.50 and reported five sales: 600 shares at a weighted-average $89.07 ($88.63–$89.53 range), 1,500 at $90.27 ($89.96–$90.95), 2,100 at $91.92 ($91.41–$92.26), 3,071 at $92.95 ($92.54–$93.53), and 229 at $93.57 ($93.54–$93.59). Across both dates, his reported sales covered 25,000 shares. The October 1 transactions were pursuant to a Rule 10b5-1 trading plan adopted November 10, 2025. A post-transaction amount includes 33,738 RSUs, each a contingent right to one common share upon vesting; they vest September 1, 2027, subject to continued employment.
Spyre Therapeutics, Inc. (SYRE) officer Heidy King-Jones reported exercising stock options for 28,399 shares of common stock at an exercise price of $14.50 per share on September 1–2, 2026, and selling 28,399 shares of common stock in multiple transactions at prices up to $90.00 per share.
The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026, with several sales reported at weighted-average prices reflecting trade ranges between $85.71 and $88.69 per share.
Spyre Therapeutics, Inc. (SYRE) reported that Chief Financial Officer Scott L. Burrows exercised stock options for 7,500 shares of common stock on September 1, 2026 at an exercise price of $14.50 per share, then sold portions of the resulting shares in multiple open-market transactions that day at weighted-average prices between $86.25 and $89.04, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. On September 2, 2026 he also sold 18,232 shares at $89.35 per share to satisfy tax withholding obligations in connection with the settlement of 33,738 restricted stock units, described as a sell-to-cover transaction rather than a discretionary trade. Following the option exercise, he continued to hold options covering 337,357 shares of common stock expiring on September 1, 2033.
Spyre Therapeutics, Inc. (SYRE) reports that Chief Executive Officer and director Turtle Cameron sold 15,000 shares of common stock on September 1, 2026 in four open-market transactions at weighted average prices of $86.36, $87.15, $88.06, and $89.07.
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025, with each price reflecting multiple trades within stated ranges. A footnote also states that Cameron has 43,593 shares scheduled to vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics, Inc. director Jeffrey W. Albers reported an option exercise and related share sales on August 7, 2026. He exercised stock options covering 5,000 shares of common stock at a $10.39 exercise price and retained options on 45,000 shares. On the same date, he reported sales totaling 23,000 shares of common stock at weighted average prices slightly above $104 per share, including sales by Sessions LLC reported as indirect ownership. All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
Spyre Therapeutics, Inc. CFO Scott L. Burrows reported an option exercise-and-sale sequence on August 3, 2026. He exercised stock options for 7,500 shares of common stock at an exercise price of $14.50 per share, then sold 7,500 shares in three transactions at weighted average prices of $95.21, $96.30 and $97.10, all pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Following the transactions, he continues to hold options covering 344,857 shares that expire on September 1, 2033 and 67,476 restricted stock units vesting in two equal installments on September 1, 2026 and 2027, subject to continued employment.
Spyre Therapeutics, Inc. CEO Cameron Turtle sold a total of 15,000 shares of common stock on August 3, 2026 in five open-market transactions under a Rule 10b5-1 trading plan adopted on June 20, 2025, at weighted average prices between $93.97 and $97.46 per share.
The sales occurred across trade ranges from $93.42 to $97.47 per share. The reported holdings include 58,108 shares that vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a pre-planned option exercise and share sale. On July 1, 2026, he exercised stock options covering 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in open-market transactions at weighted average prices of $87.55 and $88.37. These trades were made under a Rule 10b5-1 trading plan adopted on November 10, 2025. After the transactions, he directly holds 97,994 common shares, plus 67,476 restricted stock units that vest in 2026 and 2027 and 352,357 remaining option shares expiring in 2033.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.
The sales occurred on July 1, 2026 at weighted average prices of $87.52 and $88.34 per share, with individual trades ranging from $87.03 to $88.95, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. Following these transactions, Sloan reported no directly held common shares and 305,000 stock options outstanding, part of an option grant for 400,000 shares scheduled to fully vest over four years and expiring on October 1, 2034.
Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle sold 15,000 shares of common stock in three open‑market transactions on July 1, 2026. The sales were executed at weighted average prices around $87–$89 per share and were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 20, 2025.
Following these transactions, Turtle holds 582,540 shares of Spyre Therapeutics common stock directly. This amount includes 72,623 shares that vest in monthly installments through November 2026, contingent on his continued service with the company.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported an exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options to acquire 15,000 shares of common stock at an exercise price of $14.50 per share, then sold 15,000 shares in open-market transactions.
The sales comprised 10,000 shares at a weighted average price of $87.14 and 5,000 shares at $87.12, with actual trade prices ranging from $86.78 to $87.43. After these trades, he directly held 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
Burrows also continues to hold a stock option originally covering 404,857 shares, with 359,857 option shares remaining after this 15,000‑share exercise. The option had been adjusted for a 1‑for‑25 reverse stock split and vests over several years based on continued employment.
Spyre Therapeutics, Inc. reported Form 4 activity for entities associated with Fairmount Funds Management LLC. Fairmount Healthcare Fund II L.P. converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, based on a 40-to-1 conversion ratio subject to a 9.99% beneficial ownership limitation.
On the same date, Fairmount Healthcare Fund II L.P. sold 4,684,781 shares of Common Stock at $85.31 per share, leaving it with no directly held Common Stock after the transaction, while retaining indirect exposure through Series A Preferred Stock that is convertible into 13,841,800 shares of Common Stock. Fairmount, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Spyre Therapeutics director Michael Thomas Henderson reported an open-market sale of Common Stock. He sold 20,000 shares on June 22, 2026 at a price of $100.00 per share. After this transaction, he directly holds 68,606 shares of Spyre Therapeutics common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating the trades were scheduled in advance rather than timed discretionarily.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported an option exercise and related share sale. Sloan exercised stock options to acquire 8,333 shares of common stock at $27.46 per share, then sold 8,333 shares in an open‑market transaction at $75.00 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Sloan continues to hold 8,333 common shares directly and 313,334 stock options exercisable for common stock, with the option award originally covering 400,000 shares and expiring on October 1, 2034.
Spyre Therapeutics, Inc. reported that Chief Executive Officer and director Cameron Turtle sold a total of 15,000 shares of common stock in three open-market transactions on June 1, 2026 at prices ranging from the high-$60s to low-$70s per share. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025, indicating they were pre-arranged. Following the transactions, the filing shows Turtle directly holding 597,540 shares of common stock, which includes 87,138 shares that vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics (SYRE) Chief Financial Officer Scott L. Burrows exercised stock options and sold shares in a pre-planned transaction. On June 1, 2026, he exercised options to acquire 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in three open-market trades at weighted-average prices around the low $70s, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly holds 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments in 2026 and 2027, and continues to hold a large stock option covering hundreds of thousands of additional shares.
Spyre Therapeutics, Inc. reported a routine insider equity award involving director Tomas Kiselak and Fairmount-affiliated funds. An option was granted covering 8,026 shares of common stock at an exercise price of $72.51 per share, expiring on May 27, 2036. The option vests in full on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, subject to Mr. Kiselak’s continued service. Under his arrangement with Fairmount Funds Management LLC, any net cash or stock from this option is for the benefit of Fairmount-managed investment vehicles, and Mr. Kiselak disclaims beneficial ownership except for his pecuniary interest.
Spyre Therapeutics, Inc. director Jeffrey W. Albers received a stock option grant covering 8,026 shares of common stock. The option has an exercise price of $72.51 per share and expires on May 27, 2036.
The award vests and becomes fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Albers continues serving the company through that vesting date. Following this grant, he holds options for 8,026 shares directly.
Spyre Therapeutics, Inc. director Michael Thomas Henderson received a grant of stock options covering 8,026 shares of common stock. The options have an exercise price of $72.51 per share and expire on May 27, 2036. They vest and become fully exercisable on the earlier of May 27, 2027 or the company’s 2027 annual meeting of stockholders, subject to his continued service, leaving him with 8,026 options following this award.
Spyre Therapeutics, Inc. director Laurie Stelzer received a grant of stock options covering 8,026 shares of common stock. The options carry an exercise price of $72.51 per share and expire on May 27, 2036.
The award will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Stelzer continues to serve the company through that vesting date. Following this grant, she holds 8,026 options directly.
Spyre Therapeutics, Inc. director Mark C. McKenna received a grant of stock options covering 8,026 shares of common stock. These options carry an exercise price of $72.51 per share and expire on May 27, 2036.
The options will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics’ 2027 annual meeting of stockholders, provided McKenna continues serving the company through the vesting date. After this grant, he holds 8,026 derivative securities directly from this award.
Spyre Therapeutics, Inc. director Sandra Milligan received a grant of stock options covering 8,026 shares of common stock. The options have an exercise price of $72.51 per share and expire on May 27, 2036. They vest and become fully exercisable on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, contingent on her continued service.
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported open-market sales of a total of 80,000 shares of common stock on May 8, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026.
The sales were broken into four trades at weighted average prices between about $72.57 and $75.35 per share. Footnotes state that each reported price is a weighted average, with individual trades occurring in ranges from $72.03 up to $75.71 per share.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a planned option exercise and share sale on Common Stock. On May 1, 2026, he sold 12,500 shares of Common Stock in an open-market transaction at $71.37 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
The same day, he exercised stock options to acquire 12,500 shares of Common Stock at an exercise price of $14.50 per share. Following these transactions, he directly holds 97,994 shares of Common Stock, which include 67,476 restricted stock units scheduled to vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. He also retains stock options representing a right to purchase 404,857 shares of Common Stock, vesting over several years.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported coordinated stock trades involving both option exercise and share sales. On May 1, 2026, Sloan exercised stock options to acquire 78,333 shares of common stock at an exercise price of $27.46 per share.
That same day, Sloan executed multiple open-market sales totaling 78,333 shares of common stock at weighted average prices reported around the low- to mid-$70s per share, with detailed price ranges from $69.21 to $74.96 disclosed in the footnotes. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025.
The option exercised covers a grant originally for 400,000 shares of common stock, with 321,667 option shares remaining outstanding after this exercise and an expiration date of October 1, 2034, subject to continued vesting based on employment.
Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock in multiple open-market transactions on May 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan.
The sales occurred at weighted-average prices, with transaction price ranges disclosed between $69.25 and $74.96 per share across several blocks. After these transactions, the filing shows that Turtle continues to hold Spyre common stock directly.
Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock. On April 1, 2026, he sold a total of 15,000 shares of common stock in two transactions, at weighted average prices of $49.20 and $49.92 per share.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Cameron directly holds 627,540 shares of Spyre Therapeutics common stock, including 116,168 shares that vest in monthly installments through November 2026, contingent on his continued service.
Spyre Therapeutics, Inc. Chief Medical Officer Sloan Sheldon exercised stock options and sold the resulting shares. On this Form 4, Sheldon exercised options to acquire 7,958 shares of common stock at an exercise price of $21.66 per share and immediately sold all 7,958 shares at $50.00 per share.
The filing notes that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025, indicating the timing was set in advance rather than being a discretionary market-timing decision.
Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales. On April 1, 2026, he exercised stock options to acquire 7,500 shares of common stock at an exercise price of $14.50 per share, fully using the remaining options covered in this filing.
On the same date, he sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98 in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 97,994 shares of common stock, including 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported option exercises and related share sales. He exercised a stock option for 2,500 shares of common stock at $14.50 per share through a derivative conversion. On the same date, he sold a total of 2,500 shares of common stock in open-market transactions at weighted average prices of $40.56 and $41.66 per share under a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly held 97,994 shares of common stock, which the filing notes include 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The stock option originally covered 404,857 shares, with vesting over several years.
Spyre Therapeutics, Inc.'s Chief Executive Officer, Cameron Turtle, reported selling a total of 15,000 shares of common stock in open-market transactions on March 2, 2026. The sales, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, were completed in two trades at weighted average prices of $41.73 and $42.49, each reflecting multiple executions within stated price ranges. Following these transactions, the CEO directly holds 642,540 shares of common stock, which includes 130,683 shares scheduled to vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics, Inc.'s Chief Executive Officer and director Turtle Cameron reported two open-market sales of common stock. On February 2, 2026, Cameron sold 957 shares at a weighted average price of $31.82 and 14,043 shares at a weighted average price of $32.87, both coded as open-market sales.
The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. After these sales, Cameron beneficially owned 657,540 shares of common stock, which include shares scheduled to vest over approximately one year and shares acquired under the company’s employee stock purchase plan.
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported receiving 63,227 shares of common stock on January 21, 2026. The shares were received for no cash consideration through a pro-rata distribution from a limited liability company in which he is a member, rather than through an open-market purchase. Following this distribution, he beneficially owns 168,606 shares of Spyre Therapeutics common stock in direct form.
Spyre Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer, Scott L. Burrows, in a Form 4 filing. On January 9, 2026, he was granted a stock option to purchase 140,000 shares of Spyre Therapeutics common stock at an exercise price of $30.61 per share. The option is a derivative security and is held directly.
The filing states that this option will vest in equal monthly installments over four years, and each vesting installment is conditioned on his continued employment with the company at the relevant vesting date. Following this grant, Burrows beneficially owns 140,000 stock options, with the option scheduled to expire on January 9, 2036.
Spyre Therapeutics, Inc. reported that its Chief Executive Officer and director, Turtle Cameron, received a grant of stock options on 01/09/2026. The award covers 528,000 stock options, each representing the right to purchase one share of Spyre Therapeutics common stock at an exercise price of $30.61 per share, with an expiration date of 01/09/2036.
According to the filing, these options will vest in equal monthly installments over four years, and each vesting date is conditioned on Cameron’s continued employment with the company. Following this grant, Cameron beneficially owns 528,000 derivative securities directly in the form of these stock options.
Spyre Therapeutics, Inc. reported that its Chief Medical Officer, Sloan Sheldon, received a stock option grant on January 9, 2026. The award covers options to purchase 140,000 shares of Spyre’s common stock at an exercise price of $30.61 per share, expiring on January 9, 2036. Following this grant, Sloan Sheldon beneficially owns 140,000 stock options directly. The option will vest in equal monthly installments over four years, conditioned on continued employment with the company at each vesting date.
Spyre Therapeutics, Inc. reported a new stock option grant to an executive officer. Chief Legal Officer and Corporate Secretary Heidy King-Jones received a stock option covering 140,000 shares of Spyre Therapeutics common stock on 01/09/2026.
The option has an exercise price of $30.61 per share and was reported as acquired with no cash paid for the option itself. The grant vests in equal monthly installments over four years, conditioned on her continued employment with the company at each vesting date. Following this grant, she beneficially owns 140,000 derivative securities directly in the form of this option.
Spyre Therapeutics (SYRE) reported insider activity: the Chief Executive Officer and Director sold 45,000 shares of common stock on 11/03/2025 under a Rule 10b5-1 trading plan adopted on June 20, 2025. The sales comprised 28,155 shares at a weighted average price of $23.13 (range $22.51–$23.50) and 16,845 shares at a weighted average price of $23.66 (range $23.51–$24.04). Following these transactions, the reporting person beneficially owns 701,907 shares, which includes 188,743 shares scheduled to vest in monthly installments over approximately one year, subject to continued service.